Clinical Trial Update: Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Zepatier in hepatitis C-negative patients receiving heart transplants from hepatitis C-positive donors; completed Phase 1/2 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Zepatier (elbasvir/grazoprevir)

Snippet

Sponsor: University of Pennsylvania | Conditions: Heart Failure | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-02-26